- Resource
- Source: Campus Sanofi
- 8 Sept 2025
DE:RM – Dermatology Excellence: Redefining Management
DE:RM is Sanofi’s flagship annual promotional meeting, bringing together healthcare professionals from across the UK who are dedicated to the care of people living with atopic dermatitis (AD). Curated in collaboration with expert Chairs in AD management, DE:RM offers a balanced, one-day agenda featuring diverse speakers and discussion topics. The meeting explores the evolving treatment landscape, including the appropriate use of Dupixent (dupilumab) and other biologic therapies. DE:RM is designed to foster clinical excellence, collaboration, and innovation in dermatology.
Understanding Atopic Dermatitis in Skin of Colour – Teena Mackenzie
In this insightful video, Nurse Consultant Teena Mackenzie explores the unique challenges and considerations in diagnosing and treating atopic dermatitis (AD) in patients with skin of colour. Drawing from clinical experience and educational initiatives, she highlights the importance of accurate assessment, cultural sensitivity, and holistic care. The session also covers EASI scoring nuances, pigmentation differences, and the impact of underrepresentation in dermatology education and research.
Type 2 Inflammation Panel Discussion
This engaging panel discussion brings together leading dermatology and respiratory experts to explore the complexities of type 2 inflammation across multiple comorbidities, including atopic dermatitis, asthma, and eosinophilic esophagitis. Through a real-world case study of a 17-year-old patient, the panel highlights the importance of integrated care, biomarker-driven treatment decisions, and the role of DUPIXENT in managing type 2 inflammatory conditions. A must-watch for anyone looking to deepen their understanding of holistic patient management and the evolving treatment landscape.
Discover other resources
Atopic Dermatitis Control Test (ADCT)
Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.
The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.
Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.
Try the ADCTMAT-XU-2503459 (v2.0) Date of preparation: February 2026